KunleOdunsiMD

Gynecologic Oncology

Cancer Center Deputy Director, The M. Steven Piver Professor and Chair, Department of Gynecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center

Join to view full profile

Dr. Odunsi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Odunsi's full profile

Already have an account?

Office
Elm and Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-1595

Summary

Dr. Kunle Odunsi is an obstetrician/gynecologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. He received his medical degree from the University of Ife, Ile-Ife, Nigeria in 1984, completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He was admitted to the Royal College of Obstetricians and Gynecologists in 1991. Dr. Odunsi has been in practice 35 years. He specializes in gynecologic oncology and is experienced in general obstetrics and gynecology and gynecologic oncology.

Education & Training

University at BuffaloFellowship, Gynecologic Oncology, 2002
Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 1995 - 1999
Obafemi Awolowo University College of Health SciencesClass of 1984, MB Ch.B.
Obafemi Awolowo University, Ile-IfeClass of 1981, B.Sc. Health Sciences

Certifications & Licensure

IL State Medical License 2021 - 2026
NY State Medical License 1999 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Fellow (FRCOG) The Royal College of Obstetricians and Gynecologists
America's Top Doctors Castle Connolly, 2009-2014
Buffalo Spree Magazine Castle Connolly, 2008, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2008-2013
Join now to see all

Clinical Trials

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Start of enrollment: 2008 Nov 14
Completed
Phase 1
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Start of enrollment: 2012 Mar 01
Completed
Phase 1
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Start of enrollment: 2012 Aug 20
Completed
Phase 1
CT Antigen TCR-redirected T Cells for Ovarian Cancer. Start of enrollment: 2013 Jul 09
Completed
Phase 1, Phase 2
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission Start of enrollment: 2013 Dec 01
Withdrawn
Phase 1, Phase 2
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2014 Aug 25
Active, not recruiting
Early Phase 1
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Start of enrollment: 2014 Oct 10
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

664 citations
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki, Sacha Gnjatic, Paulette Mhawech-Fauceglia, Amy Beck, Austin Miller
Proceedings of the National Academy of Sciences of the United States of America. 2010-04-27
629 citations
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Ganna Chornokur, Hui-Yi Lin, Jonathan Tyrer, Kate Lawrenson, Joe Dennis
Plos One. 2015-06-19
1879 citations
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
Eiichi Sato, Sara H. Olson, Jiyoung Ahn, Brian N. Bundy, Hiroyoshi Nishikawa
Proceedings of the National Academy of Sciences of the United States of America. 2005-12-20

Journal Articles

Sialic Acid–Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments
Charles S Berenson, Kunle Odunsi, The Journal of Immunology
Variants in Genes Encoding Small GTPases and Association with Epithelial Ovarian Cancer Susceptibility
Julie M Cunningham, Robert P Edwards, Elizabeth M Poole, Tanja Pejovic, Karen Lu, Kunle Odunsi, Beth Y Karlan, Christine S Walsh, Douglas A Levine, Andrew Berchuck, Da..., PLoS One
Suppressive IL-17A+Foxp3+ and Ex-Th17 IL-17AnegFoxp3+ Treg Cells Are a Source of Tumour-Associated Treg Cells
Robert P Edwards, Tyler Curiel, Sara Berkey, David L Bartlett, Kunle Odunsi, Nature

Press Mentions

Allison Institute Announces Formation of Scientific Advisory BoardAugust 15th, 2022
Can the Vaccine Alleviate COVID Long-Haul Symptoms? • Mercy Sale Approved • UChicago Cancer Center Gets $10 Million AbbVie GrantMarch 24th, 2021

Committees

Permanent Member, National Institutes of Health, Transplantation, Tolerance, and Tumor Immunology (TTT) Study Section 2017 - Present
Member, NCI Cancer Center Subcommittee-A Initial Review Group 2017 - Present
Member, National Cancer Institute Gynecologic Cancer Steering Committee 2014 - Present
Co-Chair, National Cancer Institute Ovarian Task Force 2013 - Present
Committee Member, Institute of Medicine Committee on the State of the Science in Ovarian Cancer Research 2014 - 2016